21 April 2022 -
SHS sells shares in Bochum-based phenox GmbH, a leading manufacturer of instruments and implants for the treatment of stroke
- The fast-growing MedTech company phenox specialises in instruments and implants for the neurointerventional therapy of stroke
- With the growth capital provided by SHS et al., the Bochum-based company has developed from a start-up into a global leader in the field of stroke therapy
- A successful exit for investors from the third SHS fund generation
- The new owner targets rapid growth key markets like Europe, the US, China and Japan
Tübingen / 21.04.2022
The Tübingen-based healthcare investor SHS, which together with NRW Bank invested growth capital in the medical technology manufacturer phenox GmbH, sells its shares to the cooperation partner Wallaby Medical.
The fast-growing Bochum-based company was founded in 2005 with the aim of developing innovative technologies and solutions for the treatment of neurovascular diseases. phenox products are used in the treatment of ischaemic and haemorrhagic stroke. phenox has become a market leader in this field due to innovative products and groundbreaking technologies and is now one of the three market leaders in Europe. The buyer, Wallaby Medical, based in Laguna, California and Shanghai, China, is already a cooperation partner of phenox with joint market development in the USA and China. Together, the development of key markets in Europe, but also China and Japan, is now to be intensified.
“We are pleased to have been able to support phenox GmbH on its very successful way. It was a pleasure to work with the experienced and highly competent team led by founder and CEO Prof. Dr. Monstadt. We are sure that phenox, together with Wallaby, will continue its fast growth in other regions beyond Europe. We wish phenox and its employees all the best on their way to worldwide growth,” says the founder of the Tübingen-based healthcare investor SHS and former advisory board member of phenox, Dr. Bernhard Schirmers.
“We are very grateful for the support of SHS. Last but not least, we were also able to benefit from the fact that SHS, as an industry investor, has an international medical technology network and holds a portfolio that offers synergies,” explains phenox CEO Prof. Dr.-Ing. Monstadt.
“The investment in phenox is a great example from our portfolio that high innovative strength and management competence combined with growth capital and the network of a medtech investor can be extremely successful ” notes SHS partner Dr André Zimmermann.
SHS invested from the third SHS fund generation and an SHS parallel fund refinanced by KfW. In the 2022, this is the 2nd exit for the SHS third fund generation with a very attractive return.
About SHS Gesellschaft für Beteiligungsmanagement mbH:
“Building European Healthcare Champions” is the guiding principle of the Tübingen-based sector investor SHS. With this in mind, the investor specialising in healthcare investments finances and develops its portfolio companies. Since its foundation in 1993, the focus of its investments has been on expansion financing, shareholder changes and succession situations. In doing so, SHS takes both minority and majority stakes. Investors in SHS funds include pension funds, funds of funds, family offices, entrepreneurs, strategic investors and the SHS management team. The equity investment of the AIFM-registered company is up to EUR 20 million. Volumes exceeding this can be realised with a network of co-investors. In its investment decisions, SHS attaches great importance to the consideration of ethical aspects. The investment company is committed to the principle of Socially Responsible Investing (SRI) and is a member of UN PRI, an investor initiative launched by the UN-Environment Programme. Its members contractually agree to comply with ecological and social guidelines in their investments. Companies financed by SHS so far include, for example, Phenox GmbH from Bochum, which specializes in stroke treatments, the drug delivery expert Develco Pharma AG, which is based in Switzerland and Germany, and the Swiss company evitria AG, a global market leader in the production of customized antibodies, which SHS recently sold very successfully. SHS is currently investing from its fifth fund, which was launched in 2018.
Further information at: www.shs-capital.eu